|Takeda Supports Global Expansion of the American Cancer Society’s Relay For Life (RFL)|
New York, USA, September 12, 2016, and Osaka, Japan, September 13, 2016 – The American Cancer Society (ACS) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that Takeda will support the projected expansion of the ACS's Global Relay For Life (RFL) into an additional 20 countries by 2020. The RFL program is a global grassroots movement that unites communities across the globe to come together and honor cancer survivors, remember loved ones lost and provide an opportunity to fight back through raising awareness, fundraising and advocating for policies that help save lives.
RFL is the largest grassroots fundraiser in the world and currently brings together cancer communities in more than 26 countries. Through this expansion, RFL expects to recruit and train new partners over the next five years to increase its presence to more than 46 countries and strengthen its support for cancer patients across the globe. In addition to aiding in the expansion of RFL, Takeda's sponsorship also supplements support for regional and global summits for existing RFL partners.
"At the American Cancer Society we're laser-focused on our goal of eliminating the pain and suffering caused by cancer. The expansion of the Global Relay For Life program helps makes this possible in parts of the world facing an often staggering unequal burden of this disease," said Sharon Byers, Chief Development Officer for the American Cancer Society. "Anywhere you find a Relay For Life event, you also find cancer information, volunteer mobilization, and critical survivor support. These are necessary components for ending stigmas and saving lives. We're proud to work with Takeda to develop this cancer-fighting infrastructure in 20 additional countries and counting."
"We are proud to support the American Cancer Society to help expand the Global Relay for Life program and to raise public attention of cancer and the significant impact it has on patients, caregivers and communities across the globe," said Christophe Bianchi, Global Oncology Business Unit President, Takeda. "At Takeda's core is our unwavering commitment to patients. Through the support of this program, and in collaboration with the American Cancer Society, we hope to enhance awareness of and access to cancer prevention, early detection and treatment, and to make a meaningful difference in the lives of those impacted by cancer worldwide."
Training implemented in Uruguay
The staff and volunteer leadership from the American Cancer Society and the Peluffo-Guiguens Foundation following a two day training on Relay For Life in Montevideo, Uruguay.
Volunteers from the Peluffo-Giguens Foundation conduct a group activity on selecting the best leader for a Relay For Life Committee at the training in Montevideo, Uruguay.
About the American Cancer Society
For Takeda, Corporate Social Responsibility (CSR) is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. In addition, we strive to maintain and improve sound business processes and to engage in activities to promote a sustainable society as a good corporate citizen. In doing so, we are implementing a model of value creation and preservation. For more information, visit http://www.takeda.com/csr/policy/.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.
Takeda Pharmaceutical Company Limited